High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

<div>Definition of primary and secondary AI resistance in cases of AI as adjuvant therapy (a) and AI for metastatic breast cancer (b).</div>

International Journal of Breast Cancer

fig1

Figure 1

Figure 1: High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors 

Figure 1 | High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors 